Roche Reports 7% Sales Growth, Proposes Dividend Increase

Roche Holding AG reported better-than-expected 2024 results with sales reaching $68.7 billion, surpassing estimations and showcasing a 7% year-over-year growth at constant exchange rates. The Pharmaceuticals Division saw an 8% increase in sales, driven by strong demand for key drugs such as Vabysmo and Ocrevus, while the Diagnostics Division experienced a 4% rise despite a decline in COVID-19-related sales. The company anticipates steady profits moving into 2025, with expectations of mid-single-digit sales growth and high single-digit increases in core earnings per share. Roche's net profit for 2024 was reported at 9.2 billion Swiss francs, a decrease from the previous year, primarily due to goodwill impairments. Additionally, Roche plans to increase its dividend to CHF 9.70, marking the 38th consecutive increase. Overall, Roche's strategic focus on its product pipeline and market performance positions it well for future growth.